The Russian market for obesity treatments reached 44.6 billion roubles in 2025, according to data from analytical firm DSM Group. In 2026, sales of such drugs are expected to rise to 75 billion roubles.
Over one year, the figure could thus grow more than 1.6‑fold.
In 2025, the market expanded 2.5 times compared with 2024, DSM Group said.
Currently about 65% of the market is accounted for by semaglutide-based drugs, and another 20% by tirzepatide-based products, said analyst Alexander Khvostov. These findings are confirmed by a study from another analytical firm, RNC Pharma.
According to RNC Pharma, pharmacy sales of semaglutide and tirzepatide in Russia reached 17 billion roubles in the first quarter of 2026, compared with 5.2 billion roubles in the same period of 2025.
